Innovations in Blood-Based Biomarkers for Alzheimer’s Disease

Time: 9:30 am
day: Day Two


  • Key features of assay development of plasma p-tau181 and p-tau231 on the Simoa platform: challenges but significant progress.
  • Overview of plasma p-tau across the AD continuum: Do different epitopes provide different information at different times?
  • Head-to-head comparisons of p-tau plasma biomarkers